Vertex Announces U.S. FDA Approval for TRIKAFTA …
Dec 20, 2024 · Vertex Pharmaceuticals Incorporated Investors: [email protected] Susie Lisa, CFA: +1 617-341-6108 or Manisha Pai: +1 617-961-1899 Media: [email protected] or U.S.: 617-341-6992 Heather Nichols: +1 617-839-3607 or International: +44 20 3204 5275 Source: Vertex Pharmaceuticals Incorporated
Vertex Announces U.S. FDA Approval for TRIKAFTA ... - Business …
Dec 20, 2024 · BOSTON-- (BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA ®...
Vertex Announces U.S. FDA Approval for TRIKAFTA to Include …
5 days ago · BOSTON - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis ...
Vertex wins Trikafta expansion and approval for 'vanza triple' …
5 days ago · Vertex Pharmaceuticals Inc. notched two FDA victories on Friday for its cystic fibrosis medicines, increasing the number of patients eligible for its drugs and likely boosting its own future revenue.
Vertex Wins FDA Approval for New Cystic Fibrosis Option but
5 days ago · Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product Alyftrek, clearing the biotech to market a product designed to improve on Trikafta.. William Blair analysts see the early approval of Alyftrek, which had a PDUFA of Jan 2., 2025, as a positive for the company’s stock, though it has yet to rebound from last week’s crash following disappointing results ...
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor
6 days ago · You should not place undue reliance on these statements. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available. (VRTX-GEN) Contacts. Vertex Pharmaceuticals Incorporated Investors: [email protected] Susie Lisa, CFA: +1 617-341-6108 or …
Vertex Highlights First Oral Presentation of Phase 3 Clinical Data …
Sep 26, 2024 · Vertex will have four poster presentations that include clinical trial and real-world evidence data, three specifically on TRIKAFTA ® and one showing sustained benefits from KALYDECO ®, which is approved for treatment in the youngest ages.
Vertex announces FDA exands approval for Trikafta
Dec 20, 2024 · Vertex Pharmaceuticals announced the U.S. Food and Drug Administration has approved the expanded use of Trikafta for the treatment of people with cystic fibrosis ages 2 and older who have at...
Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis ...
Dec 20, 2024 · (RTTNews) - Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of ...
Press Release - Vertex Pharmaceuticals Newsroom
Apr 26, 2023 · Vertex Pharmaceuticals Incorporated Investors: [email protected] or Manisha Pai, +1 617-961-1899 Media: [email protected] or U.S.: 617-341-6992 or Heather Nichols: +1 617-839-3607 or International: +44 20 3204 5275 Source: Vertex Pharmaceuticals Incorporated